These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27401783)

  • 1. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for polycythemia vera.
    Tibes R; Mesa RA
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hydroxyurea resistant or intolerant polycythemia vera.
    Raman I; Pasricha SR; Prince HM; Yannakou CK
    Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of polycythaemia vera: a critical review of current data.
    McMullin MF; Wilkins BS; Harrison CN
    Br J Haematol; 2016 Feb; 172(3):337-49. PubMed ID: 26492433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
    Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
    Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.